Q1 2025 revenue declined 2.64% year-over-year to RMB 1.06 billion, with net profit stable at RMB 200 million as growth in patented and new products offset generic drug declines. Operating cash flow fell 26.39% amid higher R&D and promotion spending.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.